Novel therapeutic interventions for allergic rhinitis

Bibliography

• BOUSQUET J, VAN CAUWENBERGE P: Allergic Rhinitis and its Impact on Asthma (ARIA) WHO Position Paper. J. Allergy Clin. Immunol. (2001) 108(5 Part 2):S147-S334.
   PubMed Web of Science ®Google Scholar
• BJORKSTEN B, BRUNEKREEF B, COOKSON WO, VON MUTIUS E, STRACHAN DP: Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC II): rationale and methods. Eur. Respir. J. (2004) 24:406-412.
   PubMed Web of Science ®Google Scholar
• BUGIANI A, CAROSSO A, MIGLIORE E et al.: Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. Allergy (2005) 60:165-170.
   PubMed Web of Science ®Google Scholar
• TURKELTAUB PC: Prevalence of upper and lower respiratory conditions in the US population by social and environmental factors: data from the second National Health and Nutrition Examination Survey, 1976 to 1980 (NHANES II). Ann. Allergy (1991) 67:147-154.
   PubMedGoogle Scholar
• MELTZER EO: Quality of life in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108(1 Suppl.):S45-S53.
   PubMed Web of Science ®Google Scholar
• SCHOENWETTER WF, DUPCLAY L Jr, APPAJOSYULA S, BOTTEMAN MF, PASHOS CL: Economic impact and quality-of-life burden of allergic rhinitis. Curr. Med. Res. Opin. (2004) 20:305-317.
   PubMed Web of Science ®Google Scholar
• TRIPATHI A, PATTERSON R: Impact of allergic rhinitis treatment on quality of life. Pharmacoeconomics (2001) 19:891-899.
   PubMed Web of Science ®Google Scholar
• PAWANKAR R, YAMAGISHI S, TAKIZAWA R, YAGI T: Mast cell–IgE and mast cell–structural cell interactions in allergic airway disease. Curr. Drug Targets Inflamm. Allergy (2003) 2:303-312.
   PubMedGoogle Scholar
• Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. (2001) 344:109-113.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, VIZZACCARO A, CIRILLO I, TOSCA M, MASSOLO A, PASSALACQUA G: Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int. Arch. Allergy Immunol. (2005) 136:266-272.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: The TH1/TH2 paradigm. Immunol. Today (1997) 18:263-266.
   PubMedGoogle Scholar
• ROMAGNANI S: The role of lymphocytes in allergic disease. J. Allergy Clin. Immunol. (2000) 105:399-408.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, BUSCAGLIA S, PESCE GP et al.: Minimal persistent inflammation is present at mucosal level in asymptomatic rhinitic patients with allergy due to mites. J. Allergy Clin. Immunol. (1995) 96:971-979
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders? Allergy (2006) 61:3-14.
   PubMed Web of Science ®Google Scholar
• TAYLOR A, VERHAGEN J, AKDIS CA, AKDIS M: T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol. (2004) 135:73-82.
   PubMed Web of Science ®Google Scholar
• PASSALACQUA G, CIPRANDI G, GUERRA L, PASQUALI M, CANONICA GW: An update on the asthma–rhinitis link. Curr. Opin. Allergy Clin. Immunol. (2004) 4:177-183.
   PubMed Web of Science ®Google Scholar
• CRIMI E, MILANESE M, ODDERA S et al.: Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis. J. Appl. Physiol. (2001) 91:1029-1034.
   PubMed Web of Science ®Google Scholar
• BRAUNSTAHL GJ: The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J. Allergy Clin. Immunol. (2005) 115:142-148.
   PubMed Web of Science ®Google Scholar
• PASSALACQUA G, CIPRANDI G, CANONICA GW: United airways disease: therapeutic aspects. Thorax (2000) 55(Suppl. 2):s26-s27.
   PubMed Web of Science ®Google Scholar
• DURHAM SR: Effect of intranasal corticosteroid treatment on asthma in children and adults. Allergy (1999) 54(Suppl. 57):124-131.
   PubMed Web of Science ®Google Scholar
• CRYSTAL-PETERS J, NESLUSAN C, CROWN WH, TORRES A: Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J. Allergy Clin. Immunol. (2002) 109:57-62.
   PubMed Web of Science ®Google Scholar
• NATIONAL INSTITUTESOF HEALTH: NHLBI/WHO Workshop Report: global strategy for asthma management and prevention (GINA). Bethesda: National Heart, Lung, and Blood Institute (1995) (Publication No. 95-3659).
   Google Scholar
• GANI F, POZZI E, CRIVELLARO MA et al.: The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy (2001) 56:65-68.
   PubMed Web of Science ®Google Scholar
• CUSTOVIC A, VAN WJIK G: The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA2LEN). Allergy (2005) 60:1112-1115.
   PubMed Web of Science ®Google Scholar
• CHURCH MK: H1-antihistamines and inflammation. Clin. Exp. Allergy (2001) 31:1341-1343.
   PubMed Web of Science ®Google Scholar
• SIMONS FER: Advances in H1-antihistamines. N. Engl. J. Med. (2004) 351:2203-2217.
   PubMed Web of Science ®Google Scholar
• PASSALACQUA G, ALBANO M, CANONICA GW et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy (2000) 55:16-33.
   PubMed Web of Science ®Google Scholar
• LOCKEY RF, NIKOARA-KASTI GL, THEODOROPOULOS DS, BUKANTZ SC: Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. (2001) 87(Suppl. 1):S46-S55.
   Web of Science ®Google Scholar
• COX L, LARENAS D, NOLTE H, WELDON D, FINEGOLD I: Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. (2006) 117:1021-1035.
   PubMed Web of Science ®Google Scholar
• World Health Organization position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Malling HJ (Eds). Allergy (1998) 53(Suppl. 72):3-13.
   PubMed Web of Science ®Google Scholar
• MALLING HJ, ABREU-NOGUERA J, ALVAREZ-CUESTA E et al.: Local immunotherapy: position paper. Allergy (1998) 53:833-844.
   PubMed Web of Science ®Google Scholar
• MOLLER C, DREBORG S, FERDOUSI HA et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. (2002) 109:251-256.
   PubMed Web of Science ®Google Scholar
• NOVEMBRE E, GALLI E, LANDI F et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. (2004) 114:851-856.
   PubMed Web of Science ®Google Scholar
• CRAIG TJ, TEETS S, LEHMAN EB, CHINCHILLI VM, ZWILLICH C: Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J. Allergy Clin. Immunol. (1998) 101:633-637.
   PubMed Web of Science ®Google Scholar
• DENT G: Ciclesonide. Curr. Opin. Investig. Drugs (2002) 3:78-83.
   PubMedGoogle Scholar
• KALINER MA: Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin. Ther. (2006) 28:319-331.
   PubMed Web of Science ®Google Scholar
• SZEFLER S, ROHATAGI S, WILLIAMS J et al.: Ciclesonide, a novel inhaled steroid, does not affect hypothalamic–pitui- tary–adrenal axis function in patients with moderate-to-severe persistent asthma. Chest (2005) 128:1104-1114.
   PubMed Web of Science ®Google Scholar
• POSTMA DS, SEVETTE C, MARTINAT Y, SCHLOSSER N, AUMANN J, KAFE H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. (2001) 17:1083-1088.
   PubMed Web of Science ®Google Scholar
• CHAPMAN KR, PATEL P, D’URZO AD et al.: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy (2005) 60:330-337.
   PubMed Web of Science ®Google Scholar
• BATEMAN E, KARPEL J, CASALE T, WENZEL S, BANERJI D: Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest (2006) 129:1176-1187.
   PubMed Web of Science ®Google Scholar
• SCHMIDT BM, TIMMER W, GEORGENS AC: The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J. Clin. Pharmacol. (1999) 39:1062-1069.
   PubMed Web of Science ®Google Scholar
• Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J. Clin. Pharmacol. (2006) 46:461-467.
   PubMed Web of Science ®Google Scholar
• AHLSTROM-EMANUELSSON C, ANDERSSON M, PERSSON C, SCHREWELIUS C, GREIFF L: Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin. Exp. Allergy (2004) 34:731-735.
   PubMed Web of Science ®Google Scholar
• CHANG TW, DAVIS FM, SUN NC et al.: Monoclonal antibodies specific for human IgE producing cells: a potential therapeutic for IgE mediated diseases. Bio. Technology (1990) 8:122.
   PubMed Web of Science ®Google Scholar
• MANKAD VS, BURNS W: Omalizumab: other indications and unanswered questions. Clin.. Rev. Allergy Immunol. (2005) 29:17-30.
   PubMed Web of Science ®Google Scholar
• CASALE TB, BERNSTEIN IL, BUSSE W et al.: Use of an antiIgE monoclonal antibody in ragweed induced allergic rhinitis. J. Allergy Clin. Immunol. (1997) 100:110-121.
   PubMed Web of Science ®Google Scholar
• CHERVINSKY P, CASALE T, TOWNLEY R et al.: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. (2003) 91:160-167.
   PubMed Web of Science ®Google Scholar
• CASALE TB, CONDEMI J, LA FORCE C et al.: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA (2001) 286:2956-2967.
   PubMed Web of Science ®Google Scholar
• ADELROTH E, RAK S, HAATELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 106:253-259.
   PubMed Web of Science ®Google Scholar
• KOPP MV, BRAUBURGER J, RIEDINGER F et al.: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 110:728-735.
   PubMed Web of Science ®Google Scholar
• VIGNOLA AM, HUMBERT M, BOUSQUET J et al.: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 59:709-717.
   PubMed Web of Science ®Google Scholar
• OBA Y, SALTZMAN GA: Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J. Allergy Clin. Immunol. (2004) 114:265-269.
   PubMed Web of Science ®Google Scholar
• KALINER MA: Omalizumab and the treatment of allergic rhinitis. Curr. Allergy Asthma Rep. (2004) 4:237-244.
   PubMed Web of Science ®Google Scholar
• TILL SJ, DURHAM SR: Immunological responses to allergen immunotherapy. Clin. Allergy Immunol. (2004) 18:85-104.
   PubMedGoogle Scholar
• FRANCIS JN, TILL SJ, DURHAM SR: Induction of IL1ο+ CD4+ CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. (2003) 111:1255-1261.
   PubMed Web of Science ®Google Scholar
• ABRAMSON M, PUY RM, WEINER J: Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. (2003) 4:CD001186.
   PubMedGoogle Scholar
• PASSALACQUA G, GUERRA L, PASQUALI M, LOMBARDI C, CANONICA GW: Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma Immunol. (2004) 93:3-12.
   PubMed Web of Science ®Google Scholar
• WILSON D, LIMA MT, DURHAM SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy (2005) 60:4-12.
   PubMed Web of Science ®Google Scholar
• DI RIENZO V, MUSARRA A, SAMBUGARO R et al.: Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy (2005) 35:560-564.
   PubMed Web of Science ®Google Scholar
• FIOCCHI A, PAJNO G, LA GRUTTA S et al.: Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. (2005) 95:254-258.
   PubMed Web of Science ®Google Scholar
• COSMI L, SANTARLASCI V, ANGELI R et al.: Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10 production. Clin. Exp. Allergy (2006) 36:261-272.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, FENOGLIO D, CIRILLO I et al.: Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma Immunol. (2005) 95:38-44.
   PubMed Web of Science ®Google Scholar
• HUNTER RL: Overview of vaccine adjuvants: present and future. Vaccine (2002) 20(Suppl. 3):S7-S12.
   PubMed Web of Science ®Google Scholar
• BALDRICK P, RICHARDSON D, ELLIOT G, WHEELER A: Safety evaluation of MPL, an immunostimulatory adjuvant. Regul. Toxicol. Pharmacol. (2002) 35:398-413.
   PubMed Web of Science ®Google Scholar
• DRACHENBER KJ, WHEELER A, STUBNER P, HORAK F: A well tolerated grass pollen specific allergy vaccine containing a novel adjuvant MPL reduces allergy symptoms after only four preseasonal injections. Allergy (2001) 56:498-505.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. (2004) 113:1144-1151.
   PubMed Web of Science ®Google Scholar
• CRETICOS PS, EIDEN JJ, BROIDE DH et al.: Immunotherapy with Immunostimulatory oligonucleotides linked to purified ragweed Amb a1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J. Allergy Clin. Immunol. (2002) 109:743-744.
   Web of Science ®Google Scholar
• JUTEL M, JAEGER L, SUCK R, MEYER H, FIEBIG H, CROMWELL O: Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. (2005) 116:608-613.
   PubMed Web of Science ®Google Scholar
• OLDFIELD WL, LARCHÈ M, KAY AB: A double blind placebo controlled study of short-peptides derived from Fel d 1 iN cat allergic subjects. Lancet (2002) 360:47-53.
   PubMed Web of Science ®Google Scholar
• HORNER AA, TAKABAYASHI K, ZUBELDIA JM, RAZ E: Immunostimulatory DNA based therapeutics for experimental and clinical allergy. Allergy (2002) 57:24-29.
   PubMed Web of Science ®Google Scholar
• KAUR IP, CHOPRA K, SAINI A: Probiotics: potential pharmaceutical applications. Eur. J. Pharm. Sci. (2002) 15:1-9.
   PubMed Web of Science ®Google Scholar
• WANKE CA: Do probiotics prevent childhood illnesses? Br. Med. J. (2001) 322:1318-1319.
   PubMed Web of Science ®Google Scholar
• MAJAMAA H, ISOLAURI E: Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol. (1997) 99:179-85.
   PubMed Web of Science ®Google Scholar
• KALLOMAKI M, SALMINEN S, ARVILOMMI H et al.: Probiotics in primary prevention of atopic disease: a randomised placebo controlled trial. Lancet (2001) 357:1076-1079.
   PubMed Web of Science ®Google Scholar
• MARTINEZ FD, HOLT PG: Role of microbial burden in aetiology of allergy and asthma. Lancet (1999) 354(Suppl. 2):12-15.
   Google Scholar
• SANFILIPPO L, LI CK, SETH R et al.: Bacteroides fragilis enterotoxin induces the expression of IL8 and TGFβ by human colonic epithelial cells. Clin. Exp. Immunol. (2000) 119:456-463.
   PubMed Web of Science ®Google Scholar
• GASKINS HR: Immunological aspects of host/microbiota interactions at the intestinal epithelium. In: Gastrointestinal microbiology. Mackie RJ, White BA, Isaacson RE (Eds), International Thomson Publishing, New York, USA (1997):537-587.
   Google Scholar
• BULLENS DMA, VAN DEN KEYBUS, DILISSEN E et al.: Allergen-specific T cells from birch-pollen-allergic patients and healthy controls differ in T helper 2 cytokine and in IL-10 production. Clin. Exp. Allergy (2004) 34:879-887.
   PubMed Web of Science ®Google Scholar
• CIPRANDI G, VIZZACCARO A, CIRILLO I, TOSCA MA: Bacillus clausii effects in children with allergic rhinitis. Allergy (2005) 60:702-703.
   PubMed Web of Science ®Google Scholar
• CORRY DB, KHERADMAND F: Control of allergic airway inflammation through immunomodulation. J. Allergy Clin. Immunol. (2006) 117(Suppl. 2):S461-S464 (Mini Primer).
   PubMed Web of Science ®Google Scholar
• SUWAKI T, AGRAWAL DK, TOWNLEY RG: Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug. Int. ImmunoPharmacol. (2001) 1:2163-2171.
   PubMed Web of Science ®Google Scholar
• SANO T, NAKAMURA Y, YANAGAWA H et al.; HIGASHISHIKOKU ASTHMA RESEARCH GROUP: Add-on effects of suplatast tosilate in bronchial asthma patients treated with inhaled corticosteroids. Lung (2003) 181:227-235.
   PubMed Web of Science ®Google Scholar
• WASHIO Y, OHASHI Y, TANAKA A et al.: Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. Acta Otolaryngol. Suppl. (1998) 538:126-132.
   PubMedGoogle Scholar
• FURUKIDO K, TAKENO S, UEDA T, HIRAKAWA K, YAJIN K: Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am. J. Rhinol. (2002) 16:329-336.
   PubMedGoogle Scholar
• BOGUNIEWICZ M, SCHNEIDER LC, MILGROM H et al.: Treatment of steroid-dependent asthma with recombinant interferon-γ. Clin. Exp. Allergy (1993) 23:785-790.
   PubMed Web of Science ®Google Scholar
• KON OM, SIHRA BS, COMPTON CH, LEONARD TB, KAY AB, BARNES N: Randomised dose-ranging placebo controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet (1998) 352:1109-1113.
   PubMed Web of Science ®Google Scholar
• BRYAN SA, O’CONNOR BJ, MATTI S et al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2149-2153.
   PubMed Web of Science ®Google Scholar
• SCHMIDT BM, KUSMA M, FEURING M et al.: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108:530-536.
   PubMed Web of Science ®Google Scholar
• ERIN EM, LEAKER BR, ZACHARASIEWICZ A et al.: Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin. Exp. Allergy (2006) 36:458-464.
   PubMed Web of Science ®Google Scholar
• SAINT-MARTIN F, DUMUR JP, PEREZ I, IZQUIERDO I; FRENCH RUPATADINE-RHINITIS STUDY GROUP: A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol. (2004) 14:34-40.
   PubMed Web of Science ®Google Scholar
• KUDLACZ EM: Combined tachykinin receptor antagonists for the treatment of respiratory diseases. Expert Opin. Investig. Drugs (1998) 7(7):1055-1062.
   PubMedGoogle Scholar
• WILSON AM, ORR LC, SIMS EJ, LIPWORTH BJ: Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin. Exp. Allergy (2001) 31:61-68.
   PubMed Web of Science ®Google Scholar
• NAYAK AS, PHILIP G, LU S, MALICE MP, REISS TF; MONTELUKAST FALL RHINITIS INVESTIGATOR GROUP: Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma Immunol. (2002) 88:592-600.
   PubMed Web of Science ®Google Scholar
• DI LORENZO G, PACOR ML, PELLITTERI ME et al.: Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin. Exp. Allergy (2004) 34:259-267.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J, GAUGRIS S, KOCEVAR VS et al.: Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin. Exp. Allergy (2005) 35:723-727.
   PubMed Web of Science ®Google Scholar
• PRICE DB, SWERN A, TOZZI CA, PHILIP G, POLOS P: Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy (2006) 61:737-742.
   PubMed Web of Science ®Google Scholar
• BAENA-CAGNANI CE, BERGER WE, DU BUSKE LM et al.: Comparative effects of desloratadine versus montelukast on asthma symptoms and use of β2-agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy Immunol. (2003) 130:307-313.
   PubMed Web of Science ®Google Scholar
• REINARTZ SM, OVERBEEK SE, KLEINJAN A et al.: Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy (2005) 60:1301-1307.
   PubMed Web of Science ®Google Scholar
• LEE DK, GRAY RD, WILSON AM, ROBB FM, SOUTAR PC, LIPWORTH BJ: Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br. J. Clin. Pharmacol. (2004) 58:34-39.
   PubMedGoogle Scholar
• FAILLA M, BIONDI G, PROVVIDENZA PISTORIO M et al.: Intranasal steroid reduces exhaled bronchial cysteinyl leukotrienes in allergic patients. Clin. Exp. Allergy (2006) 36:325-330.
   PubMed Web of Science ®Google Scholar
• NATHAN RA, YANCEY SW, WAITKUS-EDWARDS K et al.: Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest (2005) 128:1910-1920.
   PubMed Web of Science ®Google Scholar
• CRYSTAL-PETERS J, NESLUSAN C, CROWN WH, TORRES A: Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J. Allergy Clin. Immunol. (2002) 109(1):57-62.
   PubMed Web of Science ®Google Scholar